CinCOR Pharma

Year Invested/Status: 2019/Passive

Motivation: Despite a multitude of approved therapeutics, patients and physicians still struggle to control hypertension – a common but highly dangerous and life-threatening disease.

Lead Program(s): CinCor baxdrostat (CIN-107) is a highly selective, oral small molecule inhibitor of aldosterone synthase currently in phase 2 of clinical development for the treatment of hypertension and other cardio-renal diseases. Baxdrostat has the potential to bring blood pressure into goal range which results in a decreased risk of negative cardiovascular outcomes.

Experience CinCor’s Journey on the CinRx Superhighway.

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES